The European Glaucoma Society (EGS), the world’s foremost learned society for glaucoma and its treatments, issued recommendations in its fifth “Terminology and Guidelines for Glaucoma” report, published in March 2021, that validate the positioning and relevance of the solutions developed by LUMIBIRD Medical.

EGS officially added SLT laser therapy as an alternative first-line treatment, and added SubCyclo (SubLiminal Cyclophotocoagulation) as a new effective non-invasive treatment option.
SLT and SubCyclo are core components of LUMIBIRD Medical’s solutions for glaucoma treatment, within the product ranges offered by both Quantel Medical and Ellex. In 2020, sales of these products represented around €20m for the Group.

For Jean-Marc Gendre, the LUMIBIRD Group’s Deputy CEO: “The recognition of the SLT laser as a recommended first-line treatment validates several years of work by our research teams and considerably strengthens this product range’s potential. It confirms LUMIBIRD Medical’s major role as an innovative technological firm committed to serving health”.
The Group’s Glaucoma Laser Assisted Solutions (GLASS) are more than ever aligned with the recommended treatment options for glaucoma.

Glaucoma is among the leading causes of blindness worldwide. The number of people with glaucoma was estimated to be 76 million in 2020 and is expected to increase to 112 million by 2040.

More information:
https://www.eugs.org/eng/egs_guidelines_reg.asp?l=1
https://pubmed.ncbi.nlm.nih.gov/24974815/